- Home
- POR vs AXSM Comparison
POR vs AXSM Comparison
Compare POR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- AXSM
- Stock Information
- Founded
- POR 1889
- AXSM 2012
- Country
- POR United States
- AXSM United States
- Employees
- POR N/A
- AXSM N/A
- Industry
- POR Electric Utilities: Central
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- AXSM Health Care
- Exchange
- POR Nasdaq
- AXSM Nasdaq
- Market Cap
- POR 4.4B
- AXSM 5.1B
- IPO Year
- POR N/A
- AXSM 2015
- Fundamental
- Price
- POR $41.12
- AXSM $108.98
- Analyst Decision
- POR Hold
- AXSM Strong Buy
- Analyst Count
- POR 11
- AXSM 17
- Target Price
- POR $46.50
- AXSM $171.65
- AVG Volume (30 Days)
- POR 1.3M
- AXSM 636.2K
- Earning Date
- POR 07-25-2025
- AXSM 08-04-2025
- Dividend Yield
- POR 5.11%
- AXSM N/A
- EPS Growth
- POR 8.87
- AXSM N/A
- EPS
- POR 2.86
- AXSM N/A
- Revenue
- POR $3,439,000,000.00
- AXSM $432,157,000.00
- Revenue This Year
- POR $5.23
- AXSM $62.84
- Revenue Next Year
- POR $4.25
- AXSM $60.02
- P/E Ratio
- POR $14.38
- AXSM N/A
- Revenue Growth
- POR 10.79
- AXSM 72.16
- 52 Week Low
- POR $39.55
- AXSM $72.21
- 52 Week High
- POR $49.85
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- POR 50.83
- AXSM 56.00
- Support Level
- POR $40.38
- AXSM $102.26
- Resistance Level
- POR $41.59
- AXSM $114.66
- Average True Range (ATR)
- POR 0.65
- AXSM 3.49
- MACD
- POR 0.14
- AXSM 0.92
- Stochastic Oscillator
- POR 76.96
- AXSM 61.89
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.